27 Oct 2025
Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes
Reported from TCT 2025
Mirvat Alasnag interviews Michael J. Mack on the PARTNER 3 Low-Risk randomised trial he presented at TCT 2025 in San Francisco.
At 7 years, SAPIEN 3 TAVR and surgery showed comparable clinical outcomes, valve durability, and patient-reported results, with both therapies maintaining excellent valve function and the early benefits seen at 1 year.
Authors
